Trinity Biotech plc said it received a Nasdaq non-compliance notice after falling below the Global Select Market’s $15 million minimum market value of publicly held shares requirement for 30 consecutive business days. The company has until Aug. 18, 2026 to regain compliance, and while its ADSs continue trading for now, it could face delisting if the deficiency is not cured or it does not qualify to transfer to the Nasdaq Capital Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9658604-en) on February 20, 2026, and is solely responsible for the information contained therein.
Comments